Foundry Return on Equity Industry-Neutral Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1LLY | ELI LILLY & CO | Healthcare | $1.11T | 17.57% |
2JNJ | JOHNSON & JOHNSON | Healthcare | $609.12B | 9.64% |
3MRK | MERCK & CO INC | Healthcare | $314.90B | 4.98% |
4RTX | RTX CORP | Industrials | $260.60B | 4.12% |
5TMUS | T-MOBILE US INC | Communication Services | $208.25B | 3.30% |
6AMGN | AMGEN INC | Healthcare | $197.69B | 3.13% |
7VZ | VERIZON COMMUNICATIONS INC | Communication Services | $182.01B | 2.88% |
8STX | SEAGATE TECHNOLOGY HOLDINGS PLC | Technology | $176.62B | 2.79% |
9ABT | ABBOTT LABORATORIES | Healthcare | $175.37B | 2.77% |
10GILD | GILEAD SCIENCES INC | Healthcare | $166.72B | 2.64% |
11T | AT&T INC | Communication Services | $151.54B | 2.40% |
12PFE | PFIZER INC | Healthcare | $142.77B | 2.26% |
13BMY | BRISTOL MYERS SQUIBB CO | Healthcare | $124.04B | 1.96% |
14VRTX | VERTEX PHARMACEUTICALS INC | Healthcare | $123.26B | 1.95% |
15SYK | STRYKER CORP | Healthcare | $122.63B | 1.94% |
16ISRG | INTUITIVE SURGICAL INC | Healthcare | $122.33B | 1.94% |
17MDT | MEDTRONIC PLC | Healthcare | $106.50B | 1.69% |
18CMCSA | COMCAST CORP | Communication Services | $84.98B | 1.34% |
19MMM | 3M CO | Industrials | $83.37B | 1.32% |
20CL | COLGATE PALMOLIVE CO | Consumer Defensive | $74.40B | 1.18% |
21HON | HONEYWELL INTERNATIONAL INC | Industrials | $71.29B | 1.13% |
22REGN | REGENERON PHARMACEUTICALS INC | Healthcare | $70.94B | 1.12% |
23TDG | TRANSDIGM GROUP INC | Industrials | $67.93B | 1.07% |
24WBD | WARNER BROS DISCOVERY INC | Communication Services | $67.37B | 1.07% |
25BSX | BOSTON SCIENTIFIC CORP | Healthcare | $65.44B | 1.04% |
26EW | EDWARDS LIFESCIENCES CORP | Healthcare | $49.36B | 0.78% |
27HEI | HEICO CORP | Industrials | $47.86B | 0.76% |
28IDXX | IDEXX LABORATORIES INC | Healthcare | $44.76B | 0.71% |
29BDX | BECTON DICKINSON & CO | Healthcare | $43.58B | 0.69% |
30TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Healthcare | $37.30B | 0.59% |
31ALNY | ALNYLAM PHARMACEUTICALS INC | Healthcare | $35.71B | 0.57% |
32ONC | BEONE MEDICINES LTD | Healthcare | $34.68B | 0.55% |
33RPRX | ROYALTY PHARMA PLC | Healthcare | $33.50B | 0.53% |
34ZTS | ZOETIS INC | Healthcare | $32.10B | 0.51% |
35BIIB | BIOGEN INC | Healthcare | $30.41B | 0.48% |
36DXCM | DEXCOM INC | Healthcare | $29.58B | 0.47% |
37RMD | RESMED INC | Healthcare | $28.86B | 0.46% |
38GEHC | GE HEALTHCARE TECHNOLOGIES INC | Healthcare | $28.69B | 0.45% |
39ROIV | ROIVANT SCIENCES LTD | Healthcare | $24.82B | 0.39% |
40FOXA | FOX CORP | Communication Services | $24.21B | 0.38% |
41FWONA | LIBERTY MEDIA CORP | Communication Services | $23.53B | 0.37% |
42UTHR | UNITED THERAPEUTICS CORP | Healthcare | $22.74B | 0.36% |
43ASTS | AST SPACEMOBILE INC | Technology | $22.43B | 0.35% |
44ROKU | ROKU INC | Communication Services | $21.32B | 0.34% |
45STE | STERIS PLC | Healthcare | $21.26B | 0.34% |
46VTRS | VIATRIS INC | Healthcare | $20.14B | 0.32% |
47ZBH | ZIMMER BIOMET HOLDINGS INC | Healthcare | $17.63B | 0.28% |
48NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.18B | 0.27% |
49CHTR | CHARTER COMMUNICATIONS INC | Communication Services | $16.16B | 0.26% |
50BBIO | BRIDGEBIO PHARMA INC | Healthcare | $15.94B | 0.25% |
51TXT | TEXTRON INC | Industrials | $15.91B | 0.25% |
52JAZZ | JAZZ PHARMACEUTICALS PLC | Healthcare | $15.53B | 0.25% |
53SOLV | SOLVENTUM CORP | Healthcare | $14.08B | 0.22% |
54COO | COOPER COMPANIES INC | Healthcare | $13.99B | 0.22% |
55ELAN | ELANCO ANIMAL HEALTH INC | Healthcare | $12.90B | 0.20% |
56ALGN | ALIGN TECHNOLOGY INC | Healthcare | $12.66B | 0.20% |
57PEN | PENUMBRA INC | Healthcare | $12.52B | 0.20% |
58GDDY | GODADDY INC | Technology | $12.49B | 0.20% |
59BAX | BAXTER INTERNATIONAL INC | Healthcare | $11.68B | 0.18% |
60CLX | CLOROX CO | Consumer Defensive | $11.65B | 0.18% |
61BMRN | BIOMARIN PHARMACEUTICAL INC | Healthcare | $11.52B | 0.18% |
62PODD | INSULET CORP | Healthcare | $11.36B | 0.18% |
63TECH | BIO-TECHNE CORP | Healthcare | $11.29B | 0.18% |
64KRYS | KRYSTAL BIOTECH INC | Healthcare | $10.46B | 0.17% |
65GMED | GLOBUS MEDICAL INC | Healthcare | $10.45B | 0.17% |
66SIRI | SIRIUS XM HOLDINGS INC | Communication Services | $10.30B | 0.16% |
67GSAT | GLOBALSTAR INC | Communication Services | $10.20B | 0.16% |
68CYTK | CYTOKINETICS INC | Healthcare | $9.98B | 0.16% |
69CORT | CORCEPT THERAPEUTICS INC | Healthcare | $9.72B | 0.15% |
70KYMR | KYMERA THERAPEUTICS INC | Healthcare | $9.52B | 0.15% |
71HALO | HALOZYME THERAPEUTICS INC | Healthcare | $9.23B | 0.15% |
72GKOS | GLAUKOS CORP | Healthcare | $9.21B | 0.15% |
73LLYVA | LIBERTY LIVE HOLDINGS INC | Communication Services | $9.09B | 0.14% |
74PTGX | PROTAGONIST THERAPEUTICS INC | Healthcare | $9.06B | 0.14% |
75SARO | STANDARDAERO INC | Industrials | $8.89B | 0.14% |
76ALKS | ALKERMES PLC | Healthcare | $8.79B | 0.14% |
77TGTX | TG THERAPEUTICS INC | Healthcare | $8.40B | 0.13% |
78RGEN | REPLIGEN CORP | Healthcare | $8.31B | 0.13% |
79IBRX | IMMUNITYBIO INC | Healthcare | $8.04B | 0.13% |
80AVAV | AEROVIRONMENT INC | Industrials | $7.20B | 0.11% |
81LQDA | LIQUIDIA CORP | Healthcare | $7.11B | 0.11% |
82LNTH | LANTHEUS HOLDINGS INC | Healthcare | $7.00B | 0.11% |
83RIOT | RIOT PLATFORMS INC | Financial Services | $6.91B | 0.11% |
84MSA | MSA SAFETY INC | Industrials | $6.60B | 0.10% |
85LOAR | LOAR HOLDINGS INC | Industrials | $6.55B | 0.10% |
86PTCT | PTC THERAPEUTICS INC | Healthcare | $6.52B | 0.10% |
87LUMN | LUMEN TECHNOLOGIES INC | Communication Services | $6.47B | 0.10% |
88CGON | CG ONCOLOGY INC | Healthcare | $6.34B | 0.10% |
89KRMN | KARMAN HOLDINGS INC | Industrials | $6.12B | 0.10% |
90LGND | LIGAND PHARMACEUTICALS INC | Healthcare | $6.08B | 0.10% |
91TFX | TELEFLEX INC | Healthcare | $5.96B | 0.09% |
92TWST | TWIST BIOSCIENCE CORP | Healthcare | $5.84B | 0.09% |
93BLCO | BAUSCH & LOMB CORP | Healthcare | $5.80B | 0.09% |
94DNTH | DIANTHUS THERAPEUTICS INC | Healthcare | $5.77B | 0.09% |
95NXST | NEXSTAR MEDIA GROUP INC | Communication Services | $5.61B | 0.09% |
96ORKA | ORUKA THERAPEUTICS INC | Healthcare | $5.59B | 0.09% |
97AIR | AAR CORP | Industrials | $5.38B | 0.09% |
98TVTX | TRAVERE THERAPEUTICS INC | Healthcare | $5.27B | 0.08% |
99CHH | CHOICE HOTELS INTERNATIONAL INC | Consumer Cyclical | $5.09B | 0.08% |
100VSNT | VERSANT MEDIA GROUP INC | Communication Services | $5.08B | 0.08% |
101KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | Healthcare | $4.92B | 0.08% |
102MMED | MINIMED GROUP INC | Healthcare | $4.75B | 0.08% |
103LIVN | LIVANOVA PLC | Healthcare | $4.43B | 0.07% |
104LBRDA | LIBERTY BROADBAND CORP | Communication Services | $4.43B | 0.07% |
105MMSI | MERIT MEDICAL SYSTEMS INC | Healthcare | $4.41B | 0.07% |
106ACAD | ACADIA PHARMACEUTICALS INC | Healthcare | $4.38B | 0.07% |
107NVST | ENVISTA HOLDINGS CORP | Healthcare | $4.35B | 0.07% |
108ICUI | ICU MEDICAL INC | Healthcare | $3.94B | 0.06% |
109TDS | TELEPHONE & DATA SYSTEMS INC | Communication Services | $3.90B | 0.06% |
110CPRX | CATALYST PHARMACEUTICALS INC | Healthcare | $3.85B | 0.06% |
111USAC | USA COMPRESSION PARTNERS LP | Energy | $3.78B | 0.06% |
112ADPT | ADAPTIVE BIOTECHNOLOGIES CORP | Healthcare | $3.67B | 0.06% |
113IRTC | IRHYTHM HOLDINGS INC | Healthcare | $3.64B | 0.06% |
114BKD | BROOKDALE SENIOR LIVING INC | Healthcare | $3.58B | 0.06% |
115ARQT | ARCUTIS BIOTHERAPEUTICS INC | Healthcare | $3.56B | 0.06% |
116MSGE | MADISON SQUARE GARDEN ENTERTAINMENT CORP | Consumer Cyclical | $3.56B | 0.06% |
117RH | RH | Consumer Cyclical | $3.55B | 0.06% |
118OGN | ORGANON & CO | Healthcare | $3.55B | 0.06% |
119HAE | HAEMONETICS CORP | Healthcare | $3.54B | 0.06% |
120LBTYA | LIBERTY GLOBAL LTD | Communication Services | $3.52B | 0.06% |
121GPCR | STRUCTURE THERAPEUTICS INC | Healthcare | $3.45B | 0.05% |
122WRBY | WARBY PARKER INC | Healthcare | $3.24B | 0.05% |
123ELVN | ENLIVEN THERAPEUTICS INC | Healthcare | $3.24B | 0.05% |
124IDYA | IDEAYA BIOSCIENCES INC | Healthcare | $3.16B | 0.05% |
125AD | ARRAY DIGITAL INFRASTRUCTURE INC | Communication Services | $3.02B | 0.05% |
126MBX | MBX BIOSCIENCES INC | Healthcare | $2.99B | 0.05% |
127DKL | DELEK LOGISTICS PARTNERS LP | Energy | $2.92B | 0.05% |
128RARE | ULTRAGENYX PHARMACEUTICAL INC | Healthcare | $2.88B | 0.05% |
129BEAM | BEAM THERAPEUTICS INC | Healthcare | $2.83B | 0.04% |
130XRAY | DENTSPLY SIRONA INC | Healthcare | $2.81B | 0.04% |
131ADEA | ADEIA INC | Technology | $2.80B | 0.04% |
132SUPN | SUPERNUS PHARMACEUTICALS INC | Healthcare | $2.79B | 0.04% |
133TRVI | TREVI THERAPEUTICS INC | Healthcare | $2.71B | 0.04% |
134GCMG | GCM GROSVENOR INC | Financial Services | $2.61B | 0.04% |
135TARS | TARSUS PHARMACEUTICALS INC | Healthcare | $2.58B | 0.04% |
136TMDX | TRANSMEDICS GROUP INC | Healthcare | $2.56B | 0.04% |
137DCO | DUCOMMUN INC | Industrials | $2.54B | 0.04% |
138CALX | CALIX INC | Technology | $2.50B | 0.04% |
139ATRO | ASTRONICS CORP | Industrials | $2.41B | 0.04% |
140VCEL | VERICEL CORP | Healthcare | $2.38B | 0.04% |
141PBH | PRESTIGE CONSUMER HEALTHCARE INC | Healthcare | $2.36B | 0.04% |
142BCRX | BIOCRYST PHARMACEUTICALS INC | Healthcare | $2.36B | 0.04% |
143LMAT | LEMAITRE VASCULAR INC | Healthcare | $2.32B | 0.04% |
144MLYS | MINERALYS THERAPEUTICS INC | Healthcare | $2.23B | 0.04% |
145SION | SIONNA THERAPEUTICS INC | Healthcare | $2.23B | 0.04% |
146HTFL | HEARTFLOW INC | Healthcare | $2.15B | 0.03% |
147AXGN | AXOGEN INC | Healthcare | $2.12B | 0.03% |
148AUPH | AURINIA PHARMACEUTICALS INC | Healthcare | $2.05B | 0.03% |
149RAPP | RAPPORT THERAPEUTICS INC | Healthcare | $2.04B | 0.03% |
150ADMA | ADMA BIOLOGICS INC | Healthcare | $2.02B | 0.03% |
151ZD | ZIFF DAVIS INC | Communication Services | $1.99B | 0.03% |
152PLSE | PULSE BIOSCIENCES INC | Healthcare | $1.98B | 0.03% |
153ABCL | ABCELLERA BIOLOGICS INC | Healthcare | $1.97B | 0.03% |
154URGN | UROGEN PHARMA LTD | Healthcare | $1.96B | 0.03% |
155ATEX | ANTERIX INC | Communication Services | $1.96B | 0.03% |
156HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.96B | 0.03% |
157CPRI | CAPRI HOLDINGS LTD | Consumer Cyclical | $1.89B | 0.03% |
158UFPT | UFP TECHNOLOGIES INC | Healthcare | $1.87B | 0.03% |
159NVCR | NOVOCURE LTD | Healthcare | $1.84B | 0.03% |
160SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.82B | 0.03% |
161ANIP | ANI PHARMACEUTICALS INC | Healthcare | $1.80B | 0.03% |
162IMCR | IMMUNOCORE HOLDINGS PLC | Healthcare | $1.78B | 0.03% |
163ATRC | ATRICURE INC | Healthcare | $1.77B | 0.03% |
164BFLY | BUTTERFLY NETWORK INC | Healthcare | $1.73B | 0.03% |
165ANAB | ANAPTYSBIO INC | Healthcare | $1.69B | 0.03% |
166EYE | NATIONAL VISION HOLDINGS INC | Consumer Cyclical | $1.66B | 0.03% |
167INVA | INNOVIVA INC | Healthcare | $1.60B | 0.03% |
168IDT | IDT CORP | Communication Services | $1.57B | 0.02% |
169XERS | XERIS BIOPHARMA HOLDINGS INC | Healthcare | $1.52B | 0.02% |
170SEPN | SEPTERNA INC | Healthcare | $1.51B | 0.02% |
171BRUN | BOOST RUN INC | Technology | $1.50B | 0.02% |
172IART | INTEGRA LIFESCIENCES HOLDINGS CORP | Healthcare | $1.50B | 0.02% |
173LILA | LIBERTY LATIN AMERICA LTD | Communication Services | $1.48B | 0.02% |
174INSP | INSPIRE MEDICAL SYSTEMS INC | Healthcare | $1.46B | 0.02% |
175AIP | ARTERIS INC | Technology | $1.43B | 0.02% |
176KMTS | KESTRA MEDICAL TECHNOLOGIES LTD | Healthcare | $1.43B | 0.02% |
177BLFS | BIOLIFE SOLUTIONS INC | Healthcare | $1.42B | 0.02% |
178PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.35B | 0.02% |
179NVAX | NOVAVAX INC | Healthcare | $1.35B | 0.02% |
180PBT | PERMIAN BASIN ROYALTY TRUST | Energy | $1.32B | 0.02% |
181STAA | STAAR SURGICAL CO | Healthcare | $1.32B | 0.02% |
182CNMD | CONMED CORP | Healthcare | $1.30B | 0.02% |
183XNCR | XENCOR INC | Healthcare | $1.30B | 0.02% |
184CDRE | CADRE HOLDINGS INC | Industrials | $1.24B | 0.02% |
185IRMD | IRADIMED CORP | Healthcare | $1.24B | 0.02% |
186AORT | ARTIVION INC | Healthcare | $1.22B | 0.02% |
187DRTS | ALPHA TAU MEDICAL LTD | Healthcare | $1.19B | 0.02% |
188TNDM | TANDEM DIABETES CARE INC | Healthcare | $1.17B | 0.02% |
189COLL | COLLEGIUM PHARMACEUTICAL INC | Healthcare | $1.17B | 0.02% |
190AVNS | AVANOS MEDICAL INC | Healthcare | $1.17B | 0.02% |
191ETON | ETON PHARMACEUTICALS INC | Healthcare | $1.16B | 0.02% |
192MGTX | MEIRAGTX HOLDINGS PLC | Healthcare | $1.15B | 0.02% |
193SECZ | SECURITIZE CORP | Technology | $1.11B | 0.02% |
194RHLD | RESOLUTE HOLDINGS MANAGEMENT INC | Industrials | $1.10B | 0.02% |
195PRCT | PROCEPT BIOROBOTICS CORP | Healthcare | $1.09B | 0.02% |
196NMAX | NEWSMAX INC | Communication Services | $1.08B | 0.02% |
197GRPN | GROUPON INC | Communication Services | $1.06B | 0.02% |
198AEVA | AEVA TECHNOLOGIES INC | Consumer Cyclical | $1.05B | 0.02% |
199PCRX | PACIRA BIOSCIENCES INC | Healthcare | $1.01B | 0.02% |
200BVS | BIOVENTUS INC | Healthcare | $1.01B | 0.02% |
201SBGI | SINCLAIR INC | Communication Services | $997M | 0.02% |
202JANX | JANUX THERAPEUTICS INC | Healthcare | $992M | 0.02% |
203EVC | ENTRAVISION COMMUNICATIONS CORP | Communication Services | $984M | 0.02% |
204VOR | VOR BIOPHARMA INC | Healthcare | $980M | 0.02% |
205GLIBA | GCI LIBERTY INC | Communication Services | $881M | 0.01% |
206TBPH | THERAVANCE BIOPHARMA INC | Healthcare | $873M | 0.01% |
207PHAT | PHATHOM PHARMACEUTICALS INC | Healthcare | $873M | 0.01% |
208AMPH | AMPHASTAR PHARMACEUTICALS INC | Healthcare | $871M | 0.01% |
209CYRX | CRYOPORT INC | Industrials | $832M | 0.01% |
210AVR | ANTERIS TECHNOLOGIES GLOBAL CORP | Healthcare | $823M | 0.01% |
211SKYH | SKY HARBOUR GROUP CORP | Industrials | $797M | 0.01% |
212SIBN | SI-BONE INC | Healthcare | $771M | 0.01% |
213BBNX | BETA BIONICS INC | Healthcare | $771M | 0.01% |
214ZVRA | ZEVRA THERAPEUTICS INC | Healthcare | $755M | 0.01% |
215RIGL | RIGEL PHARMACEUTICALS INC | Healthcare | $750M | 0.01% |
216MNPR | MONOPAR THERAPEUTICS | Healthcare | $744M | 0.01% |
217CBLL | CERIBELL INC | Healthcare | $710M | 0.01% |
218CCSI | CONSENSUS CLOUD SOLUTIONS INC | Technology | $689M | 0.01% |
219PKE | PARK AEROSPACE CORP | Industrials | $677M | 0.01% |
220CRMD | CORMEDIX INC | Healthcare | $661M | 0.01% |
221TCMD | TACTILE SYSTEMS TECHNOLOGY INC | Healthcare | $648M | 0.01% |
222SHEN | SHENANDOAH TELECOMMUNICATIONS CO | Communication Services | $630M | 0.01% |
223FAC | FACTORIAL ENERGY INC | Industrials | $610M | 0.01% |
224CEPF | CANTOR EQUITY PARTNERS IV INC | Industrials | $596M | 0.01% |
225GYRE | GYRE THERAPEUTICS INC | Healthcare | $587M | 0.01% |
226ANGO | ANGIODYNAMICS INC | Healthcare | $558M | 0.01% |
227CCOI | COGENT COMMUNICATIONS HOLDINGS INC | Communication Services | $549M | 0.01% |
228NPCE | NEUROPACE INC | Healthcare | $548M | 0.01% |
229CTNM | CONTINEUM THERAPEUTICS INC | Healthcare | $532M | 0.01% |
230XOMA | XOMA ROYALTY CORP | Healthcare | $504M | 0.01% |
231KIDS | ORTHOPEDIATRICS CORP | Healthcare | $494M | 0.01% |
232SPIR | SPIRE GLOBAL INC | Industrials | $488M | 0.01% |
233OFIX | ORTHOFIX MEDICAL INC | Healthcare | $468M | 0.01% |
234AMCX | AMC GLOBAL MEDIA INC | Communication Services | $461M | 0.01% |
235TMS | TMS INTERNATIONAL CORP | Basic Materials | $451M | 0.01% |
236SI | SHOULDER INNOVATIONS INC | Healthcare | $448M | 0.01% |
237DCTH | DELCATH SYSTEMS INC | Healthcare | $442M | 0.01% |
238PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $434M | 0.01% |
239ASMB | ASSEMBLY BIOSCIENCES INC | Healthcare | $426M | 0.01% |
240BCAR | D BORAL ARC ACQUISITION I CORP | Industrials | $420M | 0.01% |
241USNA | USANA HEALTH SCIENCES INC | Consumer Defensive | $403M | 0.01% |
242ABEO | ABEONA THERAPEUTICS INC | Healthcare | $399M | 0.01% |
243EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $394M | 0.01% |
244STRO | SUTRO BIOPHARMA INC | Healthcare | $391M | 0.01% |
245EOLS | EVOLUS INC | Healthcare | $377M | 0.01% |
246CEPT | CANTOR EQUITY PARTNERS II INC | Industrials | $376M | 0.01% |
247NATR | NATURES SUNSHINE PRODUCTS INC | Consumer Defensive | $359M | 0.01% |
248ATNI | ATN INTERNATIONAL INC | Communication Services | $356M | 0.01% |
249ELMD | ELECTROMED INC | Healthcare | $349M | 0.01% |
250CV | CAPSOVISION INC | Healthcare | $335M | 0.01% |
251CEPV | CANTOR EQUITY PARTNERS V INC | Industrials | $332M | 0.01% |
252ALDF | ALDEL FINANCIAL II INC | Industrials | $320M | 0.01% |
253CARL | CARLSMED INC | Healthcare | $317M | 0.01% |
254JACS | JACKSON ACQUISITION CO II | Industrials | $317M | 0.01% |
255FHTX | FOGHORN THERAPEUTICS INC | Healthcare | $305M | 0.00% |
256TKNO | ALPHA TEKNOVA INC | Healthcare | $291M | 0.00% |
257SGHT | SIGHT SCIENCES INC | Healthcare | $274M | 0.00% |
258QTTB | Q32 BIO INC | Healthcare | $255M | 0.00% |
259SRZN | SURROZEN INC | Healthcare | $255M | 0.00% |
260VNME | VENDOME ACQUISITION CORP I | Industrials | $254M | 0.00% |
261CXDO | CREXENDO INC | Communication Services | $248M | 0.00% |
262RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $243M | 0.00% |
263RXST | RXSIGHT INC | Healthcare | $230M | 0.00% |
264RDNW | RIDENOW GROUP INC | Consumer Cyclical | $229M | 0.00% |
265CABO | CABLE ONE INC | Communication Services | $223M | 0.00% |
266SPOK | SPOK HOLDINGS INC | Healthcare | $222M | 0.00% |
267UTMD | UTAH MEDICAL PRODUCTS INC | Healthcare | $222M | 0.00% |
268KPTI | KARYOPHARM THERAPEUTICS INC | Healthcare | $216M | 0.00% |
269KROS | KEROS THERAPEUTICS INC | Healthcare | $211M | 0.00% |
270AGEN | AGENUS INC | Healthcare | $209M | 0.00% |
271AIRO | AIRO GROUP HOLDINGS INC | Industrials | $205M | 0.00% |
272ANIK | ANIKA THERAPEUTICS INC | Healthcare | $203M | 0.00% |
273PDEX | PRO DEX INC | Healthcare | $183M | 0.00% |
274INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $180M | 0.00% |
275INGN | INOGEN INC | Healthcare | $178M | 0.00% |
276RANG | RANGE CAPITAL ACQUISITION CORP | Industrials | $171M | 0.00% |
277NMP | NMP ACQUISITION CORP | Industrials | $164M | 0.00% |
278KORE | KORE GROUP HOLDINGS INC | Communication Services | $163M | 0.00% |
279OWLT | OWLET INC | Healthcare | $162M | 0.00% |
280RCEL | AVITA MEDICAL INC | Healthcare | $157M | 0.00% |
281SIF | SIFCO INDUSTRIES INC | Industrials | $141M | 0.00% |
282VTVT | VTV THERAPEUTICS INC | Healthcare | $130M | 0.00% |
283TSQ | TOWNSQUARE MEDIA INC | Communication Services | $119M | 0.00% |
284LAKE | LAKELAND INDUSTRIES INC | Consumer Cyclical | $113M | 0.00% |
285FTLF | FITLIFE BRANDS INC | Consumer Defensive | $104M | 0.00% |
286ICCC | IMMUCELL CORP | Healthcare | $101M | 0.00% |
287RLYB | RALLYBIO CORP | Healthcare | $87M | 0.00% |
288FGMC | FG MERGER II CORP | Industrials | $86M | 0.00% |
289LFVN | LIFEVANTAGE CORP | Consumer Defensive | $78M | 0.00% |
290ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $76M | 0.00% |
291CLNN | CLENE INC | Healthcare | $76M | 0.00% |
292AIRT | AIR T INC | Industrials | $73M | 0.00% |
293SCLX | SCILEX HOLDING CO | Healthcare | $72M | 0.00% |
294SKIL | SKILLSOFT CORP | Consumer Defensive | $58M | 0.00% |
295SGA | SAGA COMMUNICATIONS INC | Communication Services | $58M | 0.00% |
296INKT | MINK THERAPEUTICS INC | Healthcare | $53M | 0.00% |
297APT | ALPHA PRO TECH LTD | Basic Materials | $53M | 0.00% |
298BKHA | BLACK HAWK ACQUISITION CORP | Industrials | $50M | 0.00% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $6.32T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 3,283-name universe at July 2026. Rows: Large ≥ $5.2B, Small < $819M. Columns: Value ≥ 0.62, Growth < 0.34 B/M. The dot marks the capital-weighted centroid of the book — 98% toward Large, 68% toward Growth. +3% unclassified (50 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 298 names now. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
2 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
The fund will not concentrate: no more than 25% of total assets in any one industry (excluding government securities and cash items).
Required<= 25.0%Actual58.4%Margin-33.4%Days required to liquidate the largest position at 20% of one day's dollar volume.
Required<= 7.0 daysActualunboundedMargin—
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 298 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 22%; both still land on the same side of the 2x limit.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 26.4% | 5.8% |
| 3 yearsp.a. | 18.7% | 1.4% |
| 5 yearsp.a. | 18.2% | 12.8% |
| 10 yearsp.a. | 16.3% | 4.0% |
| Since inceptionp.a. | 8.9% | 0.2% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 14.8% | 3.7% |
| 2025 | 7.9% | -15.2% |
| 2024 | 28.8% | 13.7% |
| 2023 | 41.0% | 24.4% |
| 2022 | -6.9% | 30.7% |
| 2021 | 30.5% | 21.9% |
| 2020 | 15.8% | -16.7% |
| 2019 | 29.1% | 0.7% |
| 2018 | -7.1% | -3.8% |
| 2017 | 20.1% | 3.3% |
| 2016 | 9.2% | -15.1% |
| 2015 | 7.0% | 14.0% |
| 2014 | 18.4% | 29.0% |
| 2013 | 36.1% | 5.0% |
| 2012 | 19.1% | 1.3% |
| 2011 | 5.0% | 1.3% |
| 2010 | 13.6% | -6.6% |
| 2009 | 24.4% | -13.2% |
| 2008 | -27.7% | 16.1% |
| 2007 | 11.6% | 7.7% |
| 2006 | 11.8% | -6.0% |
| 2005 | 3.1% | -6.9% |
| 2004 | 10.8% | -0.3% |
| 2003 | 27.2% | -5.0% |
| 2002 | -28.7% | -1.5% |
| 2001 | -13.5% | -17.7% |
| 2000 | -32.2% | -30.4% |
| 1999 | 26.3% | 1.5% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Return on Equity Industry-Neutral Factor ETF tracks a rules-based model that ranks liquid U.S. common stocks, industry-neutralized within Fama-French industries, each month by a Return on Equity signal and holds the top decile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.